<DOC>
	<DOCNO>NCT01352767</DOCNO>
	<brief_summary>A randomise , control , cross-over study inpatient outpatient phase . The inpatient phase length two day , include `` Control '' day without activate InSuPad `` Test '' day InsuPad activate . The outpatient phase length 8 week : 4 week without device- '' Control '' , 4 week device- '' Test '' .</brief_summary>
	<brief_title>The InsuPad Daily Life Study - Effect Local Heating Postprandial Glucose Excursions Using InsuPad Device</brief_title>
	<detailed_description>A randomise , control , cross-over study inpatient outpatient phase . The inpatient phase length two day , include `` Control '' day without activate InSuPad `` Test '' day InsuPad activate . The outpatient phase length 8 week : 4 week without device- '' Control '' , 4 week device- '' Test '' . Each subject randomly select one two group , group `` A '' group `` B '' . Forty ( 40 ) type I subject meet inclusion/exclusion criterion outline provide write Informed Consent enrol study . During inpatient phase subject standardize breakfast dinner venous blood sample take insulin blood glucose measurement . Comparison two day ( `` control '' `` test '' ) enable u evaluate effect device post prandial glucose level insulin level . During outpatient ( daily life ) phase subject require perform least 5 self blood glucose measurement ( SMBG ) , three meal two 90 minute post breakfast dinner . Comparing SMBG measurement two period enable u evaluate effect device post prandial glucose level . The subject contact phone study staff verify compliance protocol .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Male female patient age 18 70 year ( value include ) Type 1 diabetes mellitus insulin treat type 2 diabetes daily insulin demand ≥ 0.7 unit per kg bodyweight . 6 % ≤ HbA1c ≤ 9.5 % Use shortacting prandial insulin analogue injection Study subject willing perform least 5 blood glucose measurement per day least 56 day , willing comply study procedure keep detailed patient log book . Willing sign inform consent Excessive fibrosis , lipohypertrophy eczema injection site . Known gastro enteroparesis . Unstable chronic disease type 1 diabetes ( e.g . Unstable angina factoris , , renal disease ) last six month study start . Severe hypoglycemic event require glucagon injection glucose infusion within last four week prior study start . Hypoglycaemia unawareness ( Score &gt; 4 Hypoglycaemia Awareness Questionnaire , see appendix ) Diabetic ketoacidosis ( severe , hospitalization ) within last six month prior study start Any known lifethreatening disease Pregnant woman , lactate woman woman intend become pregnant observation period Any condition compliance issue might interfere study participation result Subjects heat sensitivity Subjects involve planed participate study Subjects incapable contracting guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>insulin injection</keyword>
</DOC>